[Epidemiologic survey of documented measles outbreak in Tehran]

Background: in spite of extended vaccination programs against measles, it is the most preventive contagious disease that leads to death. For adaptation of WHO policy for measles in Iran; we should determine susceptible age population whom at present lay out of current vaccination program

Methods and Materials: in this descriptive study which was performed in the public health School of the Tehran medical university we obtained 13 I documented measles cases among 650 suspected case of measles [as WHO discrimination] According to serum samples analysis [ capture IgM EIA 71% and 29 % HJ]

Results: in this study 63. 4 % of cases were male and 39.6 % were females. Between patients, the most prevalent age group was between 15 - 19 years old. Two peaks of the time of the disease were March and June. History of past vaccination against measles showed that 43 % had unknown history; 24. 4 % had two vaccinations 39. 3 % had one vaccination and 3.1 % had no vaccination history

Conclusions: it is suggested [by further investigations in future] the need for revaccination of measles/or age group of 15-19 in Iran will be determined

Clinical trial of triclabendazole on human fascioliasis: long term follow-up

Following an outbreak of human fascioliasis in Gilan province of Iran in 1989, the benzimidazole derivative triclabendazole [TCBZ] was suggested as the drug of choice after finding out that routine drugs were not effective. Two studies were performed: a clinical trial [before/after type] in 1989 and a historical cohort [1989 - 1995] to examine the efficacy of the drug. TCBZ was administered to 94 patients in four groups [A, B, C and D] according to the drug's instructions [time, size and frequency of dose]. The patients were followed up clinically and paraclinically for 60 days. The highest cure rate, i.e., omission of eggs and improvement of clinical symptoms [86.6%] was observed in Group A [5 mg/kg-NPO, 3 days]. Minor epigastric pain and vomiting and some urticaria was reported a few days after administration of the drug. Just a few developed cholangitis and one toxic hepatitis who were all treated satisfactorily. The second study was a 6-year follow-up survey of 50 of the 94 patients. Five cases had epigastric pain, and eggs were detected in the stool exams of two of them. Thus, by demonstrating up to 94% efficacy in the treatment of human fascioliasis in Iran [p<0.002], TCBZ is recommended as the drug of choice